Advertisement

Reactions Weekly

, Volume 1777, Issue 1, pp 2–2 | Cite as

Gastrointestinal CMV infection/reactivation with nivolumab

News item
  • 25 Downloads

Reference

  1. Medicines and Healthcare products Regulatory Agency. Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation. Drug Safety Update 13: No. 3, Oct 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/840565/Oct-2019-PDF.pdf

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations